MedTrace Logo

Mucomyst for Hepatitis C

NCT00493610 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2010-01-08

No results posted yet for this study

Summary

The study will examine the effects of treatment with N-acetylcysteine ( Mucomyst ) 1 gm twice a day for 30 dyas in 15 patients with hepatitis C. The primary outcome of interest wil be the changes in oxidant stress as measured by different oxidant stress markers level in sera. Secondary outcomes of interest will be changes in viral load of hep C and changes in liver function

Conditions

  • Hepatitis C

Interventions

DRUG

N-acetylcysteine(Mucomyst)

Sponsors & Collaborators

Principal Investigators

  • Mohammad G. Saklayen, MD · VA Medical Center, Dayton

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00493610 on ClinicalTrials.gov